Increased circulating FGF21 levels are suggested to reflect a compensatory response to metabolic disturbances in obesity and/or type 2 diabetes1, and “FGF21 resistance” is suggested to be a pathophysiological mechanism of obesity18. Here, FGF21 is linked to obesity due to melanocortin 4 receptor deficiency.